305 related articles for article (PubMed ID: 33880524)
1. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
Sacramento CQ; Fintelman-Rodrigues N; Temerozo JR; Da Silva APD; Dias SDSG; da Silva CDS; Ferreira AC; Mattos M; Pão CRR; de Freitas CS; Soares VC; Hoelz LVB; Fernandes TVA; Branco FSC; Bastos MM; Boechat N; Saraiva FB; Ferreira MA; Jockusch S; Wang X; Tao C; Chien M; Xie W; Patel D; Garzia A; Tuschl T; Russo JJ; Rajoli RKR; Pedrosa CSG; Vitória G; Souza LRQ; Goto-Silva L; Guimarães MZ; Rehen SK; Owen A; Bozza FA; Bou-Habib DC; Ju J; Bozza PT; Souza TML
J Antimicrob Chemother; 2021 Jun; 76(7):1874-1885. PubMed ID: 33880524
[TBL] [Abstract][Full Text] [Related]
2. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
Lim YS; Nguyen LP; Lee GH; Lee SG; Lyoo KS; Kim B; Hwang SB
Mol Cells; 2021 Sep; 44(9):688-695. PubMed ID: 34518443
[TBL] [Abstract][Full Text] [Related]
3. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
Simmons B; Wentzel H; Mobarak S; Eslami G; Sadeghi A; Ali Asgari A; Abbaspour Kasgari H; Tirgar Fakheri H; Merat S; Hill A
J Antimicrob Chemother; 2021 Jan; 76(2):286-291. PubMed ID: 33063117
[TBL] [Abstract][Full Text] [Related]
4. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
Eslami G; Mousaviasl S; Radmanesh E; Jelvay S; Bitaraf S; Simmons B; Wentzel H; Hill A; Sadeghi A; Freeman J; Salmanzadeh S; Esmaeilian H; Mobarak M; Tabibi R; Jafari Kashi AH; Lotfi Z; Talebzadeh SM; Wickramatillake A; Momtazan M; Hajizadeh Farsani M; Marjani S; Mobarak S
J Antimicrob Chemother; 2020 Nov; 75(11):3366-3372. PubMed ID: 32812051
[TBL] [Abstract][Full Text] [Related]
5. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
[TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
Sokhela S; Bosch B; Hill A; Simmons B; Woods J; Johnstone H; Akpomiemie G; Ellis L; Owen A; Casas CP; Venter WDF
J Antimicrob Chemother; 2022 Sep; 77(10):2706-2712. PubMed ID: 35953881
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis.
Chan HT; Chao CM; Lai CC
J Infect; 2021 Apr; 82(4):e34-e35. PubMed ID: 33373651
[No Abstract] [Full Text] [Related]
8. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
Guedj J; Dahari H; Rong L; Sansone ND; Nettles RE; Cotler SJ; Layden TJ; Uprichard SL; Perelson AS
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3991-6. PubMed ID: 23431163
[TBL] [Abstract][Full Text] [Related]
9. Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients.
Hussain N; Farooq N; Maqsood M; Rajoka MSR; Bilal M
Arch Microbiol; 2021 Jul; 203(5):2365-2371. PubMed ID: 33660021
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER).
Mobarak S; Salasi M; Hormati A; Khodadadi J; Ziaee M; Abedi F; Ebrahimzadeh A; Azarkar Z; Mansour-Ghanaei F; Joukar F; Yeganeh S; Yaghubi Kalurazi T; Naghipour M; Mehrabi Z; Bahadori AR; Yaghoubi S; Moslemi R; Abbaspour Kasgari H; Fakheri H; Moghimi M; Shabani AM; Nekoukar Z; Babamahmoodi F; Davoudi Badabi AR; Davoodi L; Hassaniazad M; Barahimi E; Tousi A; Sadeghi A; Hosamirudsari H; Ali Asgari A; Abdollahi M; Anushiravani A; Shabani M; Shokouhi S; Khajavirad N; Salehi M; Dehghan Manshadi SA; Mousavi H; Zolfaghari F; Azimi E; Zeinali A; Akbarpour E; Merat D; Eslami G; Mousaviasl S; Sayar S; Radmanesh E; Ebrahimzadeh M; Arizavi Z; Jelvay S; Salmanzadeh S; Esmaeilian H; Mobarak M; Karimi J; Poormontaseri Z; Hasooni Bahrini N; Bonyadi A; Dehghani F; Mirzaei H; Noori Jangi M; Pourmasoomi H; Rezaie Keikhaie L; Afshari M; Nateghi Baygi A; Nateghi Baygi H; Levi J; McCann K; Wentzel H; Simmons B; Hill A; Merat S
J Antimicrob Chemother; 2022 Feb; 77(3):758-766. PubMed ID: 34849957
[TBL] [Abstract][Full Text] [Related]
11. Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites.
Boson B; Denolly S; Turlure F; Chamot C; Dreux M; Cosset FL
Gastroenterology; 2017 Mar; 152(4):895-907.e14. PubMed ID: 27932311
[TBL] [Abstract][Full Text] [Related]
12. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
[TBL] [Abstract][Full Text] [Related]
14. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
[TBL] [Abstract][Full Text] [Related]
15. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
Elfiky AA; Azzam EB; Shafaa MW
Mol Divers; 2022 Feb; 26(1):171-181. PubMed ID: 33389441
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
Abbaspour Kasgari H; Moradi S; Shabani AM; Babamahmoodi F; Davoudi Badabi AR; Davoudi L; Alikhani A; Hedayatizadeh Omran A; Saeedi M; Merat S; Wentzel H; Garratt A; Levi J; Simmons B; Hill A; Tirgar Fakheri H
J Antimicrob Chemother; 2020 Nov; 75(11):3373-3378. PubMed ID: 32812025
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study.
El-Bendary M; Abd-Elsalam S; Elbaz T; El-Akel W; Cordie A; Elhadidy T; Elalfy H; Farid K; Elegezy M; El-Badrawy A; Neamatallah M; Abd Elghafar M; Salama M; AbdAllah M; Essam M; El-Shazly M; Esmat G
Expert Rev Anti Infect Ther; 2022 Feb; 20(2):291-295. PubMed ID: 34225541
[TBL] [Abstract][Full Text] [Related]
18. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
19. Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Smith MA; Regal RE; Mohammad RA
Ann Pharmacother; 2016 Jan; 50(1):39-46. PubMed ID: 26486762
[TBL] [Abstract][Full Text] [Related]
20. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
